Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interaction between angiotensin-converting enzyme 2 (ACE2) and the spike glycoprotein S1 subunit is a critical molecular event that enables the entry of coronaviruses, such as SARS-CoV-2, into host cells. The spike (S) protein of the virus contains two main subunits: S1, which mediates receptor binding, and S2, which facilitates membrane fusion. The receptor-binding domain (RBD) within the S1 subunit specifically recognizes and binds to ACE2 on host cell surfaces. Disruption or inhibition of this interface blocks infection—making it a prime target for antiviral drugs and neutralizing antibodies.
Disruption or inhibition of the ACE2-Spike S1 interaction blocks viral entry
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiotensin-converting enzyme 2–spike glycoprotein S1 subunit interaction.